Opus Genetics
Yahoo Finance • 2 months ago
RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup
Opus Genetics, Inc. (NASDAQ:IRD), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. A bullish new analyst call and a broadening gene therapy pipeline are boosting confidence in the stoc... Full story
Yahoo Finance • 2 months ago
Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
Rapidly Advancing Five IRD Programswith Four Clinical Data Readouts Expected in 2027 RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing over the Next 12 to 18 Months Cash Runway into 2029 Expected to Fund Multiple Clinical... Full story
Yahoo Finance • 4 months ago
Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases
Six-Month Clinical Data Demonstrate Restoration of Cone-Mediated Vision in Pediatric LCA5 Patients, with Sensitivity Improvements Reaching Normal Ranges Early BEST1 Data Show Visual Acuity Gains and Improved Retinal Structure, Supporting... Full story
Yahoo Finance • 4 months ago
Here is Why Opus Genetics (IRD) is One of the Best Performing NASDAQ Stocks
Opus Genetics Inc. (NASDAQ:IRD) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 6, Opus Genetics secured a financing agreement with Oberland Capital, providing up to $155 million in non-dilutive fund... Full story
Yahoo Finance • 4 months ago
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
RESEARCH TRIANGLE PARK, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blind... Full story
Yahoo Finance • 5 months ago
Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
RESEARCH TRIANGLE PARK, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent bli... Full story
Yahoo Finance • 6 months ago
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 0.7% and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 9 months ago
Opus Genetics rises as eye disease study to proceed without changes
[Arrow animation green screen, red color cartoon arrow pointing turn right on black background - 4K stock photo] kontekbrothers/iStock via Getty Images * Shares of Opus Genetics (IRD [https://seekingalpha.com/symbol/IRD]) traded higher... Full story
Yahoo Finance • 9 months ago
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small mole... Full story
Yahoo Finance • 10 months ago
Opus Genetics GAAP EPS of -$0.25 misses by $0.12, revenue of $3.08M in-line
* Opus Genetics press release [https://seekingalpha.com/pr/20303379-opus-genetics-announces-financial-results-for-third-quarter-2025-and-provides-corporate] (IRD [https://seekingalpha.com/symbol/IRD]): Q3 GAAP EPS of -$0.25 misses by $0.... Full story
Yahoo Finance • 10 months ago
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited ret... Full story
Yahoo Finance • 11 months ago
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicitiesLasting, durable responses observed out to 18 months in adult particip... Full story
Yahoo Finance • last year
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
– Phase 1/2 trial expected to initiate in 2H 2025 in patients with BEST1 inherited retinal disease RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company d... Full story
Yahoo Finance • last year
Opus Genetics earnings beat by $0.07, revenue fell short of estimates
Investing.com - Opus Genetics (NASDAQ: IRD) reported second quarter EPS of $-0.120, $0.07 better than the analyst estimate of $-0.190. Revenue for the quarter came in at $2.88M versus the consensus estimate of $4.04M. Opus Genetics’s stoc... Full story
Yahoo Finance • last year
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 - - FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation fo... Full story
Yahoo Finance • last year
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small mole... Full story
Yahoo Finance • last year
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuitySafety profile consistent with previous clinical trials and no treatment-related serious adverse events reported in the s... Full story
Yahoo Finance • last year
Opus Genetics CFO departs; Amy Rabourn named interim principal financial officer
Opus Genetics, Inc. (NASDAQ:IRD) announced Wednesday that Chief Financial Officer Nirav Jhaveri has departed the company following a termination without cause. According to a press release statement based on a filing with the Securities an... Full story
Yahoo Finance • last year
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo Phase 3 study showed patient-reported functional benefit in treating significant, chronic night driving impairm... Full story